Abcam Share Price (ABC)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Abcam	LSE:ABC	London	Ordinary Share	GB00B6774699	ORD 0.2P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	-37.00p	-2.49%	1,448.00p	107,282	14:37:36

Bid Price		Offer Price	High Price	Low Price	Open Price
1,447.00p		1,449.00p	1,481.00p	1,443.00p	1,477.00p

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	217.10	51.87	20.90	69.3	2,969.6

Related Shares
GlaxoSmithKline (GSK), AstraZeneca (AZN), Geiger Count. S (GCS), Port Erin (PEBI)

Abcam (ABC) Latest News

Abcam News

Date	Time	Source	Headline
14/8/2018	08:54	UKREG	ABCAM PLC Block listing Interim Review
02/8/2018	07:08	UKREG	ABCAM PLC Total Voting Rights
31/7/2018	06:08	ALNCF	Alliance News Flash Headline
12/7/2018	10:36	ALNC	Life Sciences Firm Abcam Expects 11% Rise In Full Year Revenue
12/7/2018	07:00	UKREG	ABCAM PLC Full Year Trading Update
03/7/2018	12:47	UKREG	ABCAM PLC Total Voting Rights
18/6/2018	16:22	ALNC	Abcam Appoints Former Celltech CFO As Non-Executive Chairman
18/6/2018	14:54	UKREG	ABCAM PLC Directorate Change
04/6/2018	08:55	UKREG	ABCAM PLC Total Voting Rights
11/5/2018	10:55	UKREG	Baillie Gifford & Co. Form 8.3 - Abcam Plc

More Abcam News

Abcam Takeover Rumours

Abcam (ABC) Share Charts

1 Year Abcam Chart

1 Month Abcam Chart

Intraday Abcam Chart

Abcam (ABC) Discussions and Chat

Abcam Forums and Chat

Date	Time	Title	Posts
31/7/2018	20:52	ABCAM with Charts & News	50
19/11/2017	20:07	Investing ? Start with your ABC's	703
03/8/2017	11:31	Abcam	-
29/8/2013	23:08	ABCAM - another e-Commerce Retailer	120
07/2/2013	17:29	abc	1

Add a New Thread

Abcam (ABC) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
13:37:09	1,448.00	108	1,563.84	AT
13:37:09	1,448.00	10	144.80	AT
13:37:09	1,448.00	40	579.20	AT
13:37:09	1,448.00	143	2,070.64	AT
13:37:09	1,448.00	272	3,938.56	AT

View all Abcam trades in real-time

Abcam (ABC) Top Chat Posts

Date	Subject
16/8/2018 09:20	Abcam Daily Update: Abcam is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker ABC. The last closing price for Abcam was 1,485p. Abcam has a 4 week average price of 1,330p and a 12 week average price of 1,186p. The 1 year high share price is 1,513p while the 1 year low share price is currently 948.50p. There are currently 205,083,170 shares in issue and the average daily traded volume is 257,995 shares. The market capitalisation of Abcam is £2,969,604,301.60. Read Full Thread Reply
03/11/2016 11:09	shawzie: I can only agree with Panmure that the current share price overvalues this Company. Earnings fairly static on increasing turnover. Intangibles increasing rapidly, but not reflected in increased earnings. Increase in Net Worth of Company due mainly to increase in Intangibles. Does anyone have a more optimistic view? Read Full Thread Follow Reply
25/1/2016 11:48	campbed: Very good trading update today outlining progress on all fronts. A great British success story . Share price at 640p almost back to the all time high of 660p reached at end of 2015 before the market-wide Jan sell off. Read Full Thread Follow Reply
12/2/2015 21:05	trident5: I've never seen a share price go round in a circle like that. Is that a good sign? Read Full Thread Follow Reply
31/1/2015 10:42	apad: Slater in the Telegraph today - with any luck that should drive the share price down for those who are looking for an entry point. apad . .R01;and some can be disastrous Other Aim shares that are favourites of veteran IHT investors are Young & Co’s Brewery, Advanced Medical Solutions and Abcam. All three are good sound companies but it seems to me that their share prices are living on the memory of their excellent past growth. Nowadays their p/e ratios are in or around the 20s with only single-digit earnings growth forecast. They are not for me because the slightest upset in their earnings growth could cause a major setback in their shares. Read Full Thread Follow Reply
22/1/2015 17:43	jeffcranbounre: Abcam is featured in today's ADVFN podcast. To listen to the podcast click here> http://bit.ly/ADVFN0113 In today's podcast: - Chris Oil, financial writer and city investor will be chatting about a well known name who could be back in fashion. Chris on Twitter is @ChrisOil - And Rodney Hobson, a financial speaker, writer and author of investment books including Shares Made Simple, the beginner's guide to the stock market. Rodney on Twitter is @RodneyHobson - The micro and macro news - Plus the broker forecasts Every Tuesday is Ten Bagger Tuesday on the podcast. If you know of a stock, whose share price has the potential to increase ten fold, just click the link below. Ten Bagger Tuesday (All it involves is filling out a form that will take you around 5 minutes and you don't personally appear on the podcast). Once a week, on a Friday, I feature a tip from a listener to this podcast, if you'd like to suggest a stock click the link below: Suggest a stock (Again all it involves is filling out a form that will take you around 5 minutes and you don't personally appear on the podcast). You can subscribe to this podcast in iTunes by clicking HERE To follow me on Twitter click HERE As a listener to the ADVFN podcast you can take advantage of some exclusive first year discounts on popular subscriptions: Bronze - £50 (normally £73.82/year) Silver - £145 (normally £173.71/year) Level 2 - £350 (normally £472.94/year) Call 0207 0700 961 and ask for the ADVFN Podcast discount to take advantage of these reduced rates or just CLICK HERE for more information. Please DO NOT buy any stock recommended in this podcast basely solely on what you hear. The opinions in this podcasts are just that, opinions. Please do you own research before investing. Justin Read Full Thread Follow Reply
22/1/2015 17:24	richscotsman: Abcam may well have it's ups and downs.... Look at the chart and it is mainly up. They do however have unique capability in a market which has long term grant funding... For me this is a safer bet in a downturn than gold but also okay generally. The fact that the bod take a view of future markets and invest in a company that they can add value to is positive. What may cost in the short term is wise in the long term. They could easily have made no progress by cutting overheads to a minimum in search of short term share price reward. The acquisition is further evidence of bod that understands the future market and can close a deal. Strip out currency and the growth is stunning. If you look forward then those currency trends may well reverse. Read Full Thread Follow Reply
20/5/2014 07:56	simon gordon: Unicorn AIM VCT - 20/5/14 Abcam (-23%) is a global leader in the supply of innovative protein research tools. In March 2014, Abcam released its financial results for the six month period ended 31 December 2013, which were in line with your Investment Manager's internal forecasts. Revenues of £61.9m (H2 2012: £57.3m) represented half-year on half-year growth of over 8%, while earnings per share were up 6.5% to 8.74p (H2 2012: 8.21p). Abcam remains a cash generative business with a robust balance sheet. Net cash balances at the period end amounted to £35.3m. Despite Abcam's many obvious qualities, market reaction to the release of Interim Results in early March was negative as investors worried about currency headwinds and the impact of possible cuts to health budgets in the key North American market, which accounts for 43% of total sales. As a result, Abcam's share price ended the period markedly lower. The holding has been retained in the portfolio in the expectation that the de-rating in the value of Abcam will prove to be temporary. Read Full Thread Follow Reply
19/4/2014 08:32	apad: IC Since releasing half-year results and exposing sluggish Asian sales, medical-proteins supplier Abcam (ABC) has seen its share price crash, tumbling 12 per cent on the morning the figures were first reported. While underlying sales still managed to grow 9 per cent in Japan during the six months to December, this did not live up to analysts' expectations and even Abcam was surprised, having previously identified US sequestration as the bigger threat to growth last year. But efforts will still be made to consolidate the group's position in China this year, with a new office in Shanghai due to open. Chief executive Jonathan Milner has said he is focused on 'getting it right' in Asia and subsequently picked up an extra £1m worth of new shares in the group after seeing the price fall and present a cheaper entry point. Before dropping to its current price of 383p, the shares carried a pretty punchy rating of 27, prompting us to maintain our bearish stance and recommend offloading more of the stock. Considering emerging markets remain crucial to the future growth of Abcam and certain parts of Asia are failing to meet ambitious expectations, the shares probably have further to fall. Sell. HR Read Full Thread Follow Reply
06/3/2014 07:27	richscotsman: Buy into Abcam as share price drops, says Numis Antibody supplier Abcam (ABC.L) has been upgraded from 'hold' to 'buy' by Numis analyst Charles Weston. Weston placed a target price of 510p on the shares despite a sharp drop in the share price earlier in the week as it revealed sluggish Japanese growth despite the Japanese government investing in research. 'We are upgrading our recommendation to 'buy', from 'hold', following the sharp fall in the share price [on Wednesday morning],' he said. 'In our view little has changed in the fundamental investment thesis for Abcam and history has taught us that periods of weakness in its share price are the right time to buy into its highly defensive business model.' Weston said he 'expected margins and cash generation to remain high due to the characteristics of the product and Abcam's digital platform' and that management's investment in new growth initiatives has 'yet to translate to accelerating growth rates, which could start to be delivered over the next six-12 months'. Read Full Thread Follow Reply
05/3/2014 08:24	apad: My take is that the important financial metric out of the interim is that the increase in staff will impact profits at these growth rates, which is why the share price fell so much on the announcement of the interims. As an "owner" I see this expenditure as vital to becoming dominant in a fragmented market. ABC's growth is dependent on increasing its market share in a market that is strongly dependent on government spending. The second string to this bow is, as buywell the second indicates, acquisitions. These acquisitions need to fit in with ABC's "postal" business model - there was some criticism of the last acquisition on this basis. I do not know how many sensible propositions are out there, which is where, rich's "trust in the management" kicks in. The smaller tech. component of my portfolio is predicated on the need for management to know their technology from soup to nuts and ABC fits snugly into this category. All of this I am comfortable with, but I do not have a clear idea about ABCAM's standing amongst its peers in this fragmented market, or the rate of change of its market share. Based on this narrative, my eleventh purchase will be at 08:05 on the morning of an acquisition announcement, iff the share price remains depressed. apad Read Full Thread Follow Reply

Abcam share price data is direct from the London Stock Exchange

add chat code

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P:41 V: D:20180816 13:54:50